

# MINDACT

## Trial Highlights

The **M**icroarray **I**n **N**ode-negative (or 1-3 positive lymph node) **D**isease may **A**void **C**hemo**T**herapy (MINDACT) clinical trial is a study to help breast cancer patients and their physicians **optimize** chemotherapy treatment decisions using **MammaPrint®**

Here is a look at some of the impressive data from this **POSITIVE** trial:

**112**  
Institutions



**6,693**



Early-stage breast cancer patients



**FDA cleared**  
Included in major guidelines



Covered by insurance\*

**46%**

of patients spared from unnecessary chemotherapy



Low Risk / High Risk results

**HIGHEST**



level of medical evidence

MammaPrint is a 70-gene test that will assess your cancer's risk of recurrence within 5-years. Patients diagnosed with stage I or II invasive breast cancer that is lymph node negative or lymph node positive (up to 3 nodes) and ≤ 5cm, are eligible for Agendia Breast Cancer testing.

### Breast Cancer recurrence assay comparison:

	MammaPrint®	Oncotype DX®
Number of genes evaluated	70	16
Number of reference (or control) genes	465	5
FDA 510(k) cleared	✓	✗
Definitive Low Risk or High Risk Results? (No intermediate / indeterminate results)	✓	✗
Results don't reassess traditional breast cancer markers ER, PR, HER2 or Ki-67?	✓	✗
Results independent of 5 years of hormonal therapy or therapy compliance? (tamoxifen or AI)	✓	✗

MammaPrint data is based off of MINDACT publication results and information from [www.agendia.com](http://www.agendia.com)  
Oncotype DX data is based off of TAILORx study results and information from [www.oncotypedx.com](http://www.oncotypedx.com)

Consult your physician to see if MammaPrint is right for you.



\*Contact our Agendia Team to discuss reimbursement



mammaprint®  
70-Gene Breast Cancer Recurrence Assay